Eupraxia’s EP-104IAR Gains Attention in Rheumatology

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.

Eupraxia Pharmaceuticals’ promising EP-104IAR treatment for knee osteoarthritis has gained attention following its publication in the prestigious Lancet Rheumatology journal. The Phase 2b trial results highlight its potential to offer significant pain relief with a favorable safety profile. This development could mark a significant advancement in the treatment of knee osteoarthritis, affecting over 30 million people in the U.S.

For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.